Results 31 to 40 of about 186,761 (273)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. [PDF]

, 2019
BackgroundNovel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor ...
Bajorin, DF, Bellmunt, J, Choueiri, TK, Climent, MA, Culine, S, de Wit, R, Fong, L, Fradet, Y, Frenkl, TL, Gerritsen, W, Gurney, H, Lee, JL, Nam, K, Necchi, A, Perini, RF, Petrylak, DP, Quinn, DI, Sternberg, CN, Vaughn, DJ, Vogelzang, NJ   +19 more
core   +1 more source

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

OncoImmunology, 2022
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover ...
Tianying Su, George E. Duran, Alexa C. Kwang, Nirasha Ramchurren, Steven P. Fling, Youn H. Kim, Michael S. Khodadoust   +6 more
doaj   +1 more source

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Journal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer.
Teppei Sugano, Masahiro Seike, Yoko Funasaka, Mai Yoshida, Ryoko Takayama, Ken Okamura, Asuka Nakanishi, Toru Tanaka, Susumu Takeuchi, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Hidehisa Saeki, Akihiko Gemma   +13 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2023
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival ...
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn   +19 more
doaj   +1 more source

Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? [PDF]

, 2019
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors.
Alessandra Cassano, Apte, Bill, Blom, Brigida Anna Maiorano, De Vries, Durie, Emilio Bria, Ericsson, Ernesto Rossi, Giampaolo Tortora, Gianluigi Petrone, Giovanni Schinzari, Guido Rindi, Ilaria Grazia Zizzari, Lagouros, Makitie, Maria Antonietta Blasi, Maria Grazia Sammarco, Marianna Nuti, Monica Maria Pagliara, Shaw, Sohn, Vincenzo Fiorentino, Whelchel   +24 more
core   +1 more source

Immunotherapy, Inflammation and Colorectal Cancer. [PDF]

, 2020
Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States.
Karin, Michael, Lichtenstern, Charles Robert, Ngu, Rachael Katie, Shalapour, Shabnam   +3 more
core   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Frontiers in Oncology, 2023
BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil ...
Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, Gleicy M. Hair   +6 more
doaj   +1 more source

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources